Tyr42
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr42  -  GAPDH (human)

Site Information
DPFIDLNyMVyMFQy   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450511

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 3 ) , mass spectrometry ( 2 , 4 , 5 , 6 ) , mutation of modification site ( 1 , 3 ) , western blotting ( 3 )
Disease tissue studied:
leukemia ( 4 ) , acute myelogenous leukemia ( 4 ) , lymphoma ( 6 ) , anaplastic large cell lymphoma ( 6 ) , ovarian cancer ( 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 ) , KURAMOCHI (ovarian) ( 2 ) , NOMO-1 (myeloid) ( 4 ) , NRK (fibroblast) ( 3 ) , SU-DHL1 (T lymphocyte) ( 5 , 6 )

Upstream Regulation
Putative in vivo kinases:
Src (human) ( 1 )
Kinases, in vitro:
Src (human) ( 3 )
Treatments:
MMS ( 1 ) , PP2 ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on GAPDH:
intracellular localization ( 1 , 3 )
Effects of modification on biological processes:
apoptosis, inhibited ( 1 ) , DNA repair, induced ( 1 )
Induce interaction with:
PKCI (rat) ( 3 )

References 

1

Ci S, et al. (2020) Src-mediated phosphorylation of GAPDH regulates its nuclear localization and cellular response to DNA damage. FASEB J 34
32539222   Curated Info

2

Ren H (2010) CST Curation Set: 10755; Year: 2010; Biosample/Treatment: cell line, KURAMUCHI/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Tisdale EJ, Artalejo CR (2007) A GAPDH mutant defective in Src-dependent tyrosine phosphorylation impedes Rab2-mediated events. Traffic 8, 733-41
17488287   Curated Info

4

Cherry J (2007) CST Curation Set: 2522; Year: 2007; Biosample/Treatment: cell line, Nomo-1/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Rush J, et al. (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23, 94-101
15592455   Curated Info

6

Moritz A (2003) CST Curation Set: 166; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.